AZ-WORLD-VIEW
17.3.2022 15:46:04 CET | Business Wire | Press release
World View , an expert in stratospheric exploration on a mission to help spaceflight participants rediscover Earth, today announces the debut of its spaceflight capsule prototype. The announcement marks another exciting milestone for the company, following recent news of its entry into the space tourism sector and appointment of President of Tourism and Exploration, Dale Hipsh.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220317005669/en/
Spaceflight participants eagerly awaiting the launch of commercial flights beginning in 2024 are provided a first-look at the distinctive World View experience, from onboard amenities and design touches to the superior hospitality and life-changing perspectives enjoyed throughout the journey.
“Unveiling our space capsule prototype is a pivotal moment for the company as we continue to prepare for our first launch from the Grand Canyon in just two short years,” said Ryan Hartman, President and Chief Executive Officer of World View. “We are thrilled to partner with leaders in aerospace design and engineering to bring our vision to life and ensure spaceflight participants enjoy a truly transformative experience.”
The exterior of the World View space capsule is shaped like a faceted hexagon with softened edges and a pearlescent white finish, which offers thermal management properties but also enhances the geometric detailing and curves. It boasts large elliptical windows that measure approximately 6.5 feet wide x 4.5 feet high, framing impressive views of the Earth’s curvature and its natural wonders. When seats are in a reclined position, the sky window on top of the capsule provides passengers an exciting line of sight to the balloon lifting them as well as constellations upon reaching float altitude. The central ceiling pelmet also includes a mood wash light that changes in accordance with the stage in flight to provide optimal viewing out of the capsule’s windows.
The capsule is climate-controlled and pressurized with an entire interior designed to maximize space, allowing spaceflight participants to move freely and comfortably about the capsule. The color palette, materials and finishes create an environment of calm, with clean lines, soft tones and clever concealment of functional elements–such as lavatory and galley entrances–so the focus remains on the stunning vistas and sights outside. Aligned with World View’s commitment to sustainability, great care is being taken to ensure materials are sourced from sustainable vendors whenever possible and options for re-use or recycling are being thoroughly explored.
Luxurious, ergonomic seating for eight passengers is configured in pairs, with an additional pair designated for crew members. Amenities including a cocktail table, graphical user interface (GUI) screen (providing educational materials and engaging activities), central console, personal storage and beverage holder, are at spaceflight participants’ fingertips to ensure that no moment of the journey is missed. Each capsule is outfitted with an onboard telescope to maximize viewing throughout the journey. Spaceflight participants will also enjoy gourmet custom dining options and top-shelf libations throughout their flight and each capsule will be equipped with streaming and mobile communication capabilities to stay in touch with loved ones back on Earth.
Projected lift off is scheduled before dawn, providing participants a front row seat to the sunrise on most flights. Along the journey, passengers will take in the curvature of the Earth, thin blue line of the atmosphere, vast darkness of space and constellations. Without the typical turbulence found on an airplane flight, spaceflight participants will be able to stand and move about the craft shortly after launch. The onboard crew, including one pilot and one concierge, serve as both Earth and space guides, cross-trained in flight operations, hospitality and medical support.
World View’s space tourism program begins launching commercial flights in 2024 with voyages taking off from natural and man-made wonders such as the Grand Canyon and Great Barrier Reef. Flights will lift passengers in a zero-pressure stratospheric balloon and pressurized space capsule to 100,000 feet altitude, nearly 23 miles above Earth, for an unparalleled experience that will last six to eight hours. Participants will fully experience and immerse themselves in the beauty, fragility, history and importance of the areas surrounding each location and of the Earth itself.
Design elements and engineering considerations continue to be refined. Further information on World View available at worldview.space .
ABOUT WORLD VIEW
World View is the leading stratospheric exploration company on a mission to inspire the global community to rediscover Earth. Through both its legacy Stratollite imaging and newly launched space tourism and exploration businesses, World View is working to ensure its ultimate objective: honor the planet so that future generations will feel blessed to call it home. For more information, visit worldview.space .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220317005669/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom